JNJ

176.81

-0.44%↓

NVS

122.7

+0.1%↑

ABT

133.07

+0.29%↑

TMO

477.64

+0.38%↑

ISRG

434.46

-1.69%↓

JNJ

176.81

-0.44%↓

NVS

122.7

+0.1%↑

ABT

133.07

+0.29%↑

TMO

477.64

+0.38%↑

ISRG

434.46

-1.69%↓

JNJ

176.81

-0.44%↓

NVS

122.7

+0.1%↑

ABT

133.07

+0.29%↑

TMO

477.64

+0.38%↑

ISRG

434.46

-1.69%↓

JNJ

176.81

-0.44%↓

NVS

122.7

+0.1%↑

ABT

133.07

+0.29%↑

TMO

477.64

+0.38%↑

ISRG

434.46

-1.69%↓

JNJ

176.81

-0.44%↓

NVS

122.7

+0.1%↑

ABT

133.07

+0.29%↑

TMO

477.64

+0.38%↑

ISRG

434.46

-1.69%↓

Home・Aandelen Lijst・Sage Therapeutics Inc

Sage Therapeutics Inc

Open

SectorGezondheidszorg

8.69

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.69

Max

8.69

Dividenden
By Dow Jones
Volgende Winsten	28 okt 2025

Nieuwssentiment

By Acuity

100%

365 / 375 Rangschikking in Healthcare

Sage Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

31 jul 2025, 23:56 UTC

Populaire aandelen

Stocks to Watch: Amazon, Bio-Rad, Coinbase, Mercer

31 jul 2025, 23:48 UTC

Marktinformatie

Scentre Can Beat Annual Earnings Guidance -- Market Talk

31 jul 2025, 23:45 UTC

Marktinformatie

Nikkei May Decline Amid Caution Over Earnings, Domestic Politics -- Market Talk

31 jul 2025, 23:37 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

31 jul 2025, 23:37 UTC

Marktinformatie

Gold Steady as Traders Eye Tariff-Deal Developments -- Market Talk

31 jul 2025, 23:12 UTC

Winsten

OCBC: Evolving Trade, Monetary Policies, Persistent Geopolitical Tensions Expected to Weigh on Growth Prospects >O39.SG

31 jul 2025, 23:10 UTC

Winsten

Oversea-Chinese Banking: Declining Interest-Rate Environment Weighed in Net Interest Income >O39.SG

31 jul 2025, 23:09 UTC

Winsten

Oversea-Chinese Banking 2Q Net Interest Income S$2.28B Vs. S$2.43B >O39.SG

31 jul 2025, 23:08 UTC

Winsten

Oversea-Chinese Banking 2Q Total Income S$3.55B Vs. S$3.63B >O39.SG

31 jul 2025, 23:08 UTC

Winsten

Oversea-Chinese Banking 2Q Net S$1.82B Vs. Net S$1.94B >O39.SG

31 jul 2025, 23:01 UTC

Winsten

Amazon Posts Higher Sales, Profit -- 3rd Update

31 jul 2025, 22:08 UTC

Marktinformatie

Winsten

Amazon CEO Impressed by Deals Signed for Project Kuiper -- Market Talk

31 jul 2025, 22:02 UTC

Marktinformatie

Winsten

Apple's FY Outlook Shows Sales Growth Won't Last -- Market Talk

31 jul 2025, 21:57 UTC

Marktinformatie

Winsten

Amazon CEO Sees Strong Early Demand for Alexa+ -- Market Talk

31 jul 2025, 21:50 UTC

Winsten

Amazon Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

31 jul 2025, 21:43 UTC

Winsten

Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs -- 2nd Update

31 jul 2025, 21:29 UTC

Winsten

Amazon to Invest More in Chips, Data Centers Amid Generative AI Opportunity, CFO Says

31 jul 2025, 21:26 UTC

Winsten

Apple Expects Revenue to Grow in Mid- to High-Single Digits in Current Quarter, CFO Says

31 jul 2025, 21:26 UTC

Winsten

MicroStrategy Beats Earnings Estimates. The Stock Rises. -- Barrons.com

31 jul 2025, 21:22 UTC

Winsten

Amazon Has Impressive Amount of Agreements for Project Kuiper, CEO Says

31 jul 2025, 21:19 UTC

Winsten

Apple Estimates Tariff Impact to Add $1.1B to Costs in Current Quarter, CEO Says

31 jul 2025, 21:19 UTC

Winsten

Apple Incurred $800M in Tariff-Related Costs in 2Q, CEO Says

31 jul 2025, 21:14 UTC

Winsten

Amazon's AWS is Seeing More Demand Than Supply, CEO Says

31 jul 2025, 21:12 UTC

Winsten

Amazon Saw Record Prime Sign-Ups in 3 Weeks Before Prime Day, CEO Says

31 jul 2025, 21:10 UTC

Winsten

Amazon Just Getting Started on Automation, Robotics to Boost Efficiency, CEO Says

31 jul 2025, 21:09 UTC

Winsten

Amazon Delivered to Prime Members at Record Pace in 2Q, CEO Says

31 jul 2025, 21:09 UTC

Winsten

Amazon CEO Sees Diversity of Sellers as Advantage for Inflation-Weary Consumers

31 jul 2025, 21:08 UTC

Winsten

Apple iPhone Revenue Performance Driven by Popularity of iPhone 16 Family, CEO Says

31 jul 2025, 21:08 UTC

Winsten

Amazon CEO Sees Strong Customer Adoption of Perishables Same-Day Delivery Pilot

31 jul 2025, 21:05 UTC

Winsten

Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs -- Update

Peer Vergelijking

Prijswijziging

Sage Therapeutics Inc Prognose

Over Sage Therapeutics Inc

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.